(MedPage Today) -- Rivaroxaban cut CV events in coronary and peripheral disease patients
via CardioBrief: Enormous NOAC Study Halted for 'Overwhelming Efficacy'
by
Showing posts with label CardioBrief: Enormous NOAC Study Halted for 'Overwhelming Efficacy'. Show all posts
Showing posts with label CardioBrief: Enormous NOAC Study Halted for 'Overwhelming Efficacy'. Show all posts
Wednesday, February 8, 2017
Subscribe to:
Posts (Atom)